Roche Holding reports divarasib results. Roche Holding stock trades at EUR 436.23
Published on 10/25/2026 at 17:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDivarasib study results and dates
- On October 25, 2026, Roche reported a 44 percent reduction in the risk of death in its divarasib study.
- Roche Holding stock traded at EUR 436.23 in weekend trading at 5:56 p.m. CEST on October 25, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Roche Holding announced pivotal divarasib results from the phase III Krascendo 1 study on October 25, 2026, according to GlobeNewswire. The company said divarasib reduced the risk of death by 44 percent compared with sotorasib or adagrasib. At the same time, Roche Holding stock traded at EUR 436.23 in weekend trading at Lang & Schwarz at 5:56 p.m. CEST on October 25, 2026.
The week in figures
Lang & Schwarz quoted Roche Holding at EUR 436.23 in weekend trading at 5:56 p.m. CEST on October 25, 2026. The quote is a euro indication for investors in Germany while Xetra is closed.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Roche Holding stock.
Chronology of the week
On October 25, 2026, Roche said divarasib produced a median overall survival of 17.7 months in the Krascendo 1 study, compared with 12.0 months in the control arm. The release said the data were presented during the 2026 ESMO Congress and published simultaneously in The New England Journal of Medicine. The company also reported a 42 percent reduction in the risk of disease progression or death. These details were published by GlobeNewswire.
Market context: Market report SMI.
Dates of the coming week
The 2026 ESMO Congress is scheduled to run through October 27, 2026, according to the Roche release. The next Xetra session is scheduled for October 26, 2026.
